InsiderPulse
Dashboard

VERA

Vera Therapeutics, Inc.

Health CareRussell 2000

Vera Therapeutics, Inc. insider trading

Vera Therapeutics, Inc. files with the SEC as a Pharmaceutical Preparations company headquartered in Brisbane, CA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent VERA insider transactions

7 insiders traded VERA on the open market between Feb 23, 2026 and Sep 15, 2026 — 20 sales worth $7.1M, of which 13 were pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$7.1M

13 of 20 on a 10b5-1 plan

Net
−$7.1M
Insiders
7

Open-market purchases (code P) and sales (code S) from Vera Therapeutics, Inc.'s own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 23, 2026. The live dashboard shows new filings the moment they clear.

Every VERA Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

VERA insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 10 insiders traded VERA on the open market: 5 purchases worth $5.5M and 74 sales worth $17.6M, 64 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 1 purchase ($250K) and 19 sales ($5.7M), by 9 insiders.

QuarterBoughtSold
Q2 2026—−$2.4M7 sales · all on a plan
Q1 2026—−$1.4M7 sales
Q4 2025+$250K1 buy−$1.9M5 sales · 3 on a plan
Q3 2025——
Q2 2025+$5.3M4 buys—
Q1 2025—−$1.3M6 sales · all on a plan
Q4 2024—−$6.1M31 sales · all on a plan
Q3 2024—−$4.5M18 sales · 17 on a plan
Largest purchase
+$2.9M of VERA by Enright Patrick G (Director) on Jun 23, 2025.
Largest sale
−$710.5K of VERA by Fordyce Marshall (President And CEO · Director) on Feb 23, 2026.

Open-market transactions through Jun 30, 2026most recent first

  • Fordyce Marshall10b5-1

    President And CEO · Director

    −$698.4K

    Jun 23, 2026

    18,412 sh · $37.93

  • Fordyce Marshall10b5-1

    President And CEO · Director

    −$521K

    May 12, 2026

    14,219 sh · $36.64

  • Fordyce Marshall10b5-1

    President And CEO · Director

    −$158.8K

    May 12, 2026

    4,281 sh · $37.09

  • Fordyce Marshall10b5-1

    President And CEO · Director

    −$616.9K

    Apr 14, 2026

    14,130 sh · $43.66

  • Fordyce Marshall10b5-1

    President And CEO · Director

    −$353.1K

    Apr 14, 2026

    7,921 sh · $44.58

  • Fordyce Marshall10b5-1

    President And CEO · Director

    −$41K

    Apr 14, 2026

    900 sh · $45.51

  • Fordyce Marshall

    President And CEO · Director

    −$710.5K

    Feb 23, 2026

    16,925 sh · $41.98

  • Grant Sean

    Chief Financial Officer

    −$207.8K

    Feb 23, 2026

    4,949 sh · $41.98

  • Young Joseph R

    SVP, Finance, Chief Acct Offcr

    −$130.9K

    Feb 23, 2026

    3,117 sh · $41.98

  • Johnson David Lee

    Chief Operating Officer

    −$108.3K

    Feb 23, 2026

    2,579 sh · $41.98

  • Turner William D.

    Chief Regulatory Officer

    −$91.8K

    Feb 23, 2026

    2,187 sh · $41.98

  • Brenner Robert

    Chief Medical Officer

    −$90.3K

    Feb 23, 2026

    2,151 sh · $41.98

  • Skelton Laurence Matthew

    Chief Commercial Officer

    −$66.4K

    Feb 23, 2026

    1,582 sh · $41.98

  • Turner William D.10b5-1

    Chief Regulatory Officer

    −$500.8K

    Dec 15, 2025

    10,000 sh · $50.08

  • Enright Patrick G

    Director

    +$250K

    Dec 11, 2025

    5,882 sh · $42.50

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Vera Therapeutics, Inc. company record

SEC industry classification
Pharmaceutical Preparations
Headquarters
Brisbane, CA
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0001831828

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought VERA

What the stock actually did in the 90 days following each open-market purchase

Don't check VERA — let it ping you

Get told the moment an insider moves on VERA

Pro watches Vera Therapeutics, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add VERA to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track VERA on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read VERA insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

VKTXXENEZLABATTODNTHUTHRCORTHRMYSUPNOMCLHQYDOCS
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are VERA insiders buying or selling?
Between Feb 23, 2026 and Sep 15, 2026, 7 Vera Therapeutics, Inc. insiders made no open-market purchases and 20 sales worth $7.1M, a net sale of $7.1M. 13 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much VERA stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 10 Vera Therapeutics, Inc. insiders made 5 open-market purchases worth $5.5M and 74 sales worth $17.6M. 64 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: 1 purchase ($250K) and 19 sales ($5.7M). The largest purchase was Enright Patrick G buying $2.9M on Jun 23, 2025. The largest sale was Fordyce Marshall selling $710.5K on Feb 23, 2026.
What was the largest recent VERA insider trade?
Fordyce Marshall (President And CEO · Director) sold $1.4M of VERA stock on Jul 07, 2026 at about $42.07 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy VERA shares?
No open-market purchase by a Vera Therapeutics, Inc. insider appears in the filings from Feb 23, 2026 to Sep 15, 2026 — every recorded open-market transaction in that period was a sale. Before that, the most recent purchase in SEC's data was Enright Patrick G buying $250K on Dec 11, 2025.
Where does VERA insider trading data come from?
From the Form 4 filings Vera Therapeutics, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.